211 related articles for article (PubMed ID: 18397705)
1. Successful treatment of nephrotic syndrome due to systemic AL amyloidosis after autologous stem cell transplantation: renal response is an important therapeutic end point.
Akay OM; Sahin G; Kabukcuoglu S; Yalcin AU; Gulbas Z
Clin Nephrol; 2008 Apr; 69(4):294-7. PubMed ID: 18397705
[TBL] [Abstract][Full Text] [Related]
2. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation.
Gono T; Matsuda M; Dohi N; Hoshi K; Tada T; Sakashita K; Koike K; Aizawa M; Ikeda S
Intern Med; 2003 Jan; 42(1):72-7. PubMed ID: 12583623
[TBL] [Abstract][Full Text] [Related]
3. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.
Dember LM; Sanchorawala V; Seldin DC; Wright DG; LaValley M; Berk JL; Falk RH; Skinner M
Ann Intern Med; 2001 May; 134(9 Pt 1):746-53. PubMed ID: 11329232
[TBL] [Abstract][Full Text] [Related]
4. A long-term remission of renal amyloidosis with nephrotic syndrome after autologous peripheral blood stem-cell transplantation.
Ogawa K; Ikeda K; Furukawa M; Harada-Shirado K; Mashimo Y; Takahashi H; Matsumoto H; Kimura S; Shichishima-Nakamura A; Ohkawara H; Hashimoto Y; Asahi K; Noji H; Ohto H; Takeishi Y
Fukushima J Med Sci; 2010 Dec; 56(2):151-6. PubMed ID: 21502717
[TBL] [Abstract][Full Text] [Related]
5. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
6. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
7. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.
Comenzo RL; Vosburgh E; Simms RW; Bergethon P; Sarnacki D; Finn K; Dubrey S; Faller DV; Wright DG; Falk RH; Skinner M
Blood; 1996 Oct; 88(7):2801-6. PubMed ID: 8839879
[TBL] [Abstract][Full Text] [Related]
8. [White blood cell lysis syndrome after autologous peripheral blood stem cell transplantation in the treatment of renal AL amyloidosis. Case report].
Gatica A; Bertin P; Tagle R
Rev Med Chil; 2006 Jun; 134(6):763-6. PubMed ID: 17130952
[TBL] [Abstract][Full Text] [Related]
9. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation.
Ogita M; Hoshino J; Sogawa Y; Sawa N; Katori H; Takemoto F; Ubara Y; Hara S; Miyakoshi S; Takaichi K
Clin Nephrol; 2007 Sep; 68(3):171-6. PubMed ID: 17915620
[TBL] [Abstract][Full Text] [Related]
10. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.
Sezer O; Schmid P; Shweigert M; Heider U; Eucker J; Harder H; Sinha P; Radtke H; Possinger K
Bone Marrow Transplant; 1999 May; 23(9):967-9. PubMed ID: 10338056
[TBL] [Abstract][Full Text] [Related]
11. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL).
Gertz MA; Lacy MQ; Gastineau DA; Inwards DJ; Chen MG; Tefferi A; Kyle RA; Litzow MR
Bone Marrow Transplant; 2000 Nov; 26(9):963-9. PubMed ID: 11100275
[TBL] [Abstract][Full Text] [Related]
12. Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan.
Kawai Y; Kinoshita K; Arai H; Kuwata A; Fukuoka Y; Yamaoka M; Imamura S; Tsutani H; Ueda T
Eur J Haematol; 2004 Jun; 72(6):448-50. PubMed ID: 15128426
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.
Mollee PN; Wechalekar AD; Pereira DL; Franke N; Reece D; Chen C; Stewart AK
Bone Marrow Transplant; 2004 Feb; 33(3):271-7. PubMed ID: 14647248
[TBL] [Abstract][Full Text] [Related]
14. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
[TBL] [Abstract][Full Text] [Related]
15. [Primary systemic AL amyloidosis with remarkable calcification in the spleen].
Uchiyama K; Tsukada N; Miyazaki K; Abe Y; Sekine R; Nakagawa Y; Suzuki K
Rinsho Ketsueki; 2014 Mar; 55(3):334-9. PubMed ID: 24681937
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of AL amyloidosis.
Sezer O; Eucker J; Jakob C; Possinger K
Clin Nephrol; 2000 Jun; 53(6):417-23. PubMed ID: 10879660
[TBL] [Abstract][Full Text] [Related]
17. Recovery of acute renal failure and nephrotic syndrome following autologous stem cell transplantation for primary (AL) amyloidosis.
Snanoudj R; Mamzer-Bruneel MF; Hermine O; Grunfeld JP; Chauveau D
Nephrol Dial Transplant; 2003 Oct; 18(10):2175-7. PubMed ID: 13679499
[No Abstract] [Full Text] [Related]
18. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
19. AL amyloidosis with renal involvement.
Rysavá R
Kidney Blood Press Res; 2007; 30(6):359-64. PubMed ID: 17851224
[TBL] [Abstract][Full Text] [Related]
20. Nephrotic syndrome due to primary systemic AL amyloidosis, successfully treated with VAD (vincristine, doxorubicin and dexamethasone) alone.
Matsuda M; Gono T; Katoh N; Yoshida T; Tazawa K; Shimojima Y; Ishii W; Fushimi T; Ikeda S
Intern Med; 2008; 47(6):543-9. PubMed ID: 18344643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
